Econ Financial Services Corp Increases Stake in Amgen Inc. $AMGN

Econ Financial Services Corp grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 24.3% during the 4th quarter, Holdings Channel reports. The fund owned 8,480 shares of the medical research company’s stock after buying an additional 1,660 shares during the period. Econ Financial Services Corp’s holdings in Amgen were worth $2,776,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of AMGN. Board of the Pension Protection Fund purchased a new stake in shares of Amgen in the 4th quarter worth $26,000. Olistico Wealth LLC bought a new position in Amgen in the 4th quarter worth $33,000. Holos Integrated Wealth LLC purchased a new position in Amgen during the fourth quarter valued at $37,000. Howard Hughes Medical Institute bought a new stake in Amgen during the second quarter valued at about $32,000. Finally, Cloud Capital Management LLC bought a new stake in Amgen during the third quarter valued at about $34,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several recent research reports. Truist Financial raised their price objective on Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research note on Thursday, January 8th. Wells Fargo & Company boosted their price objective on Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a research note on Thursday, March 19th. Citigroup increased their target price on shares of Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Wall Street Zen cut shares of Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. Finally, Royal Bank Of Canada lifted their price target on shares of Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $354.60.

Amgen Price Performance

NASDAQ:AMGN opened at $351.85 on Wednesday. The business’s 50-day simple moving average is $363.37 and its two-hundred day simple moving average is $331.58. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29. The stock has a market cap of $189.67 billion, a PE ratio of 24.73, a P/E/G ratio of 3.46 and a beta of 0.45. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same quarter in the prior year, the company posted $5.31 earnings per share. The business’s quarterly revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.84%.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Positive cardiovascular data for Amgen’s Repatha: a trial showed a 31% reduction in first major cardiovascular events in a high‑risk population without known significant atherosclerosis — a tailwind for Repatha’s commercial outlook and long‑term revenue potential. Amgen: Repatha Cuts Risk…
• Positive Sentiment: High‑profile media/analyst praise has supported sentiment — Jim Cramer noted Amgen as an attractive large‑cap biotech holding, and Zacks highlighted Amgen’s resilient drug portfolio as offsetting industry headwinds. Those endorsements can boost short‑term demand. Amgen (AMGN) Stock Up Since Jim Cramer Said…
• Positive Sentiment: Zacks analyst commentary reiterates AMGN’s upside from a diversified drug portfolio and steady cash flows, supporting the stock amid sector volatility. The Zacks Analyst Blog Roche Holding, AT&T and Amgen
• Neutral Sentiment: Sector news (other biotech trial readouts and IPO activity) is driving broader health‑care flows but is not specific to Amgen’s fundamentals; watch market‑wide risk appetite. Viridian tumbles on positive data for key eye drug prospect
• Negative Sentiment: FDA safety warning on Tavneos (Amgen’s drug for certain rare autoimmune diseases): regulators identified dozens of drug‑induced liver injury cases (reports cite ~76 cases) and urged close monitoring and prompt discontinuation if liver damage is suspected — a material safety/regulatory overhang that could affect prescribing, labeling, and long‑term sales. US FDA warns of liver injury cases tied to Amgen’s rare disease drug
• Negative Sentiment: Competitive pressure: Teva’s FDA approval of a Prolia (denosumab) biosimilar and other biosimilar filings increase competition in bone‑health markets, which could weigh on Amgen’s Prolia pricing and market share over time. TEVA’s Prolia Biosimilar Gets FDA Nod, Xolair Filing Accepted

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.